UBN2

Summary

UBN2 (ubinuclein 2, HGNC:21931) is a protein-coding gene on chromosome 7q34, encoding Ubinuclein-2 (Q6ZU65).

Predicted to be involved in chromatin organization. Located in nucleoplasm.

Source: NCBI Gene 254048 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 214 total — 1 likely-pathogenic
• Dosage sensitivity (ClinGen): haploinsufficiency little evidence, triplosensitivity no evidence
• MANE Select transcript: NM_173569

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21931
Approved symbol	UBN2
Name	ubinuclein 2
Location	7q34
Locus type	gene with protein product
Status	Approved
Aliases	FLJ25778, KIAA2030
Ensembl gene	ENSG00000157741
Ensembl biotype	protein_coding
OMIM	613841
Entrez	254048

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 retained_intron

ENST00000473989, ENST00000483726, ENST00000486663, ENST00000609762, ENST00000896062, ENST00000896063

RefSeq mRNA: 1 — MANE Select: NM_173569 NM_173569

CCDS: CCDS43655

Canonical transcript exons

ENST00000473989 — 18 exons

Exon	Start	End
ENSE00001034663	139273297	139273410
ENSE00001034670	139279318	139279360
ENSE00001034672	139272322	139272440
ENSE00001034673	139269394	139269523
ENSE00001034675	139273931	139274074
ENSE00001209187	139283024	139284574
ENSE00001216442	139282005	139282055
ENSE00001216456	139276097	139276147
ENSE00001347624	139266333	139266403
ENSE00001369176	139261252	139261741
ENSE00001370910	139293889	139293981
ENSE00001391038	139293232	139293463
ENSE00001419086	139258488	139258625
ENSE00001419770	139259267	139259370
ENSE00001420725	139251956	139252057
ENSE00003596902	139231237	139231952
ENSE00003667858	139237005	139237097
ENSE00003705875	139297787	139308236

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 96.00.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.1424 / max 114.2033, expressed in 1717 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
81433	7.1429	1661
81432	1.0346	563
81434	0.6983	318
81435	0.2666	93

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
upper arm skin	UBERON:0004263	96.00	gold quality
caput epididymis	UBERON:0004358	95.97	gold quality
corpus epididymis	UBERON:0004359	95.75	gold quality
cauda epididymis	UBERON:0004360	94.12	gold quality
sperm	CL:0000019	93.83	gold quality
bronchial epithelial cell	CL:0002328	93.70	gold quality
bronchus	UBERON:0002185	93.45	gold quality
sural nerve	UBERON:0015488	93.43	gold quality
trabecular bone tissue	UBERON:0002483	93.20	gold quality
kidney epithelium	UBERON:0004819	93.00	gold quality
upper leg skin	UBERON:0004262	92.78	gold quality
skin of hip	UBERON:0001554	92.23	gold quality
mucosa of paranasal sinus	UBERON:0005030	91.98	gold quality
cerebellar vermis	UBERON:0004720	91.77	gold quality
tibialis anterior	UBERON:0001385	91.38	gold quality
ileal mucosa	UBERON:0000331	91.32	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	91.21	gold quality
deltoid	UBERON:0001476	90.92	gold quality
medial globus pallidus	UBERON:0002477	90.69	gold quality
tendon of biceps brachii	UBERON:0008188	90.64	gold quality
globus pallidus	UBERON:0001875	90.34	gold quality
nipple	UBERON:0002030	90.31	gold quality
cardiac muscle of right atrium	UBERON:0003379	90.06	gold quality
lower lobe of lung	UBERON:0008949	89.96	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	89.79	gold quality
pancreatic ductal cell	CL:0002079	89.73	gold quality
corpus callosum	UBERON:0002336	89.46	gold quality
biceps brachii	UBERON:0001507	89.36	gold quality
thymus	UBERON:0002370	89.15	gold quality
cardia of stomach	UBERON:0001162	89.03	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.21

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

503 targeting UBN2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298

Functional genomics

ClinGen dosage: haploinsufficiency 1 (little evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 1)

• MiR-455-3p mediates PPARalpha through UBN2 to promote apoptosis and autophagy in acute myeloid leukemia cells. (PMID:37805161)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ubn2a	ENSDARG00000063062
danio_rerio	ubn2b	ENSDARG00000100508
mus_musculus	Ubn2	ENSMUSG00000038538
rattus_norvegicus	Ubn2	ENSRNOG00000005564

Paralogs (1): UBN1 (ENSG00000118900)

Protein

Protein identifiers

Ubinuclein-2 — Q6ZU65 (reviewed: Q6ZU65)

All UniProt accessions (3): C9J6Y5, Q6ZU65, H7C4P8

UniProt curated annotations — full annotation on UniProt →

Tissue specificity. Expressed in several cell lines tested, including primary and transformed cell lines.

Similarity. Belongs to the ubinuclein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6ZU65-1	1	yes
Q6ZU65-2	2

RefSeq proteins (1): NP_775840* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR014840	HRD	Domain
IPR026947	UBN_middle_dom	Domain

Pfam: PF08729, PF14075

UniProt features (40 total): compositionally biased region 15, modified residue 12, region of interest 8, splice variant 2, chain 1, cross-link 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6ZU65-F1	52.08	0.09

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (13): 13, 243, 250, 252, 311, 416, 419, 422, 584, 1068, 1123, 1148, 272

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 181 (showing top): PATIL_LIVER_CANCER, GOBP_REGULATION_OF_CHROMATIN_ORGANIZATION, GOBP_PROTEIN_DNA_COMPLEX_ORGANIZATION, GOBP_CHROMATIN_REMODELING, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, MARTENS_BOUND_BY_PML_RARA_FUSION, GOBP_NUCLEOSOME_ORGANIZATION, CSR_EARLY_UP.V1_DN, BARX1_TARGET_GENES, CIITA_TARGET_GENES, CREB3L4_TARGET_GENES, DLX4_TARGET_GENES, FEV_TARGET_GENES, FOXN3_TARGET_GENES, HOXC6_TARGET_GENES

GO Biological Process (1): chromatin organization (GO:0006325)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): obsolete extracellular space (GO:0005615), nucleus (GO:0005634), nucleoplasm (GO:0005654)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular component organization	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1042 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
UBN2	CABIN1	Q9Y6J0	838
UBN2	KLRG2	A4D1S0	657
UBN2	ZBTB2	Q8N680	566
UBN2	HIRA	P54198	515
UBN2	FAM47A	Q5JRC9	505
UBN2	PHF3	Q92576	479
UBN2	LMOD2	Q6P5Q4	435
UBN2	DMRTC1	Q5HYR2	427
UBN2	ASF1A	Q9Y294	422
UBN2	MED13L	Q71F56	396
UBN2	DIP2C	Q9Y2E4	393
UBN2	C1orf74	Q96LT6	378
UBN2	FMC1	Q96HJ9	377
UBN2	PXT1	Q8NFP0	377
UBN2	C7orf33	Q8WU49	374

IntAct

80 interactions, top by confidence:

A	B	Type	Score
ASF1A	HAT1	psi-mi:“MI:0914”(association)	0.640
ASF1B	HAT1	psi-mi:“MI:0914”(association)	0.640
TFAP4	ANGPTL7	psi-mi:“MI:0914”(association)	0.640
HIRA	UBN2	psi-mi:“MI:0915”(physical association)	0.560
BAG2	HGS	psi-mi:“MI:0914”(association)	0.530
RBBP4	TNRC18	psi-mi:“MI:0914”(association)	0.530
HMGA1	MACROH2A1	psi-mi:“MI:0914”(association)	0.530
ALX3	CRTAP	psi-mi:“MI:0914”(association)	0.530
HIRA	CSPG5	psi-mi:“MI:0914”(association)	0.530
TEAD2	TEAD1	psi-mi:“MI:0914”(association)	0.530
ASF1A	MCM4	psi-mi:“MI:0914”(association)	0.530
EN1	NFIB	psi-mi:“MI:2364”(proximity)	0.470
H3C1	SMCHD1	psi-mi:“MI:2364”(proximity)	0.410
Set	ZKSCAN1	psi-mi:“MI:0914”(association)	0.350
ASF1A	CDAN1	psi-mi:“MI:0914”(association)	0.350
ORF73	ECI2	psi-mi:“MI:0914”(association)	0.350
TCF7L2	LOC401309	psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
EN1	RPA1	psi-mi:“MI:0914”(association)	0.350
KLF16		psi-mi:“MI:0914”(association)	0.350
TLX1	IGF2BP3	psi-mi:“MI:0914”(association)	0.350
CALD1		psi-mi:“MI:0914”(association)	0.350
CALM3	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
CAPZB	ENAH	psi-mi:“MI:0914”(association)	0.350
CTTN		psi-mi:“MI:0914”(association)	0.350
DBNL	ZNF536	psi-mi:“MI:0914”(association)	0.350

BioGRID (127): UBN2 (Affinity Capture-MS), UBN2 (Proximity Label-MS), UBN2 (Proximity Label-MS), UBN2 (Affinity Capture-MS), UBN2 (Affinity Capture-MS), UBN2 (Affinity Capture-MS), UBN2 (Affinity Capture-MS), UBN2 (Affinity Capture-MS), UBN2 (Affinity Capture-MS), UBN2 (Affinity Capture-MS), UBN2 (Affinity Capture-MS), UBN2 (Affinity Capture-MS), UBN2 (Affinity Capture-MS), UBN2 (Affinity Capture-RNA), UBN2 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GTU1, A2AUY4, B7ZS37, D3Z8Y2, D4A4L4, D4A666, E1B7L7, O46385, O60293, O75152, O95425, P0DQW0, Q08AZ1, Q3KQW7, Q3U1C4, Q3UH68, Q3ZC82, Q4G0F8, Q4V9H5, Q5F3Z9, Q5NBX1, Q5REG6, Q5ZJJ1, Q5ZM88, Q61464, Q62394, Q68FE9, Q6NZF1, Q6PJT7, Q6ZQ03, Q6ZU65, Q76L83, Q7TMD5, Q8BHZ4, Q8BJ05, Q8BLG0, Q8BZ32, Q8C9B9, Q8CCJ9, Q8K298

Diamond homologs: D4A666, E1B7L7, P25992, Q4G0F8, Q6ZU65, Q80WC1, Q9NPG3

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
UBN2	“form complex”	“HIRA complex 2”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 116 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Dengue Virus-Host Interactions	10	5.5×	7e-03

GO biological processes:

GO term	Partners	Fold	FDR
nucleosome assembly	10	12.9×	4e-06
mRNA transport	5	12.1×	6e-03
chromatin remodeling	9	6.0×	3e-03
transcription by RNA polymerase II	9	5.8×	3e-03
mRNA processing	8	5.8×	7e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

214 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	167
Likely benign	11
Benign	11

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
689795	NM_173569.4(UBN2):c.2024+1G>A	Likely pathogenic

SpliceAI

2809 predictions. Top by Δscore:

Variant	Effect	Δscore
7:139236989:A:AG	acceptor_gain	1.0000
7:139236990:T:G	acceptor_gain	1.0000
7:139236993:A:AG	acceptor_gain	1.0000
7:139236993:ACCTT:A	acceptor_gain	1.0000
7:139236994:C:G	acceptor_gain	1.0000
7:139236997:T:TA	acceptor_gain	1.0000
7:139237000:A:AG	acceptor_gain	1.0000
7:139237003:A:AG	acceptor_gain	1.0000
7:139237004:G:GG	acceptor_gain	1.0000
7:139237004:GAAGA:G	acceptor_gain	1.0000
7:139237093:AATAT:A	donor_gain	1.0000
7:139237094:ATAT:A	donor_gain	1.0000
7:139237095:TAT:T	donor_gain	1.0000
7:139237096:AT:A	donor_gain	1.0000
7:139237096:ATGTG:A	donor_loss	1.0000
7:139237097:TGTG:T	donor_loss	1.0000
7:139237098:G:A	donor_loss	1.0000
7:139237098:G:GG	donor_gain	1.0000
7:139237099:TGAGT:T	donor_loss	1.0000
7:139237102:G:C	donor_loss	1.0000
7:139251950:TTGCA:T	acceptor_loss	1.0000
7:139251951:TGCA:T	acceptor_loss	1.0000
7:139251952:GCA:G	acceptor_loss	1.0000
7:139251953:CA:C	acceptor_loss	1.0000
7:139251954:A:AT	acceptor_loss	1.0000
7:139251954:AG:A	acceptor_gain	1.0000
7:139251954:AGGGT:A	acceptor_gain	1.0000
7:139251955:G:GT	acceptor_loss	1.0000
7:139251955:GG:G	acceptor_gain	1.0000
7:139251955:GGGT:G	acceptor_gain	1.0000

AlphaMissense

8700 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:139252016:G:C	G208R	1.000
7:139252019:T:C	Y209H	1.000
7:139252032:A:G	D213G	1.000
7:139252037:T:C	F215L	1.000
7:139252038:T:C	F215S	1.000
7:139252038:T:G	F215C	1.000
7:139252039:T:A	F215L	1.000
7:139252039:T:G	F215L	1.000
7:139252041:T:A	I216N	1.000
7:139252043:G:C	D217H	1.000
7:139252044:A:C	D217A	1.000
7:139252044:A:G	D217G	1.000
7:139252044:A:T	D217V	1.000
7:139252048:C:A	N218K	1.000
7:139252048:C:G	N218K	1.000
7:139252049:T:C	S219P	1.000
7:139258488:T:C	Y222H	1.000
7:139258491:G:C	D223H	1.000
7:139258492:A:C	D223A	1.000
7:139258492:A:T	D223V	1.000
7:139258498:T:C	L225S	1.000
7:139258501:T:A	V226D	1.000
7:139258503:C:A	P227T	1.000
7:139258504:C:A	P227H	1.000
7:139258504:C:G	P227R	1.000
7:139258513:T:C	L230P	1.000
7:139258528:G:A	G235E	1.000
7:139258528:G:T	G235V	1.000
7:139258530:G:C	G236R	1.000
7:139258531:G:A	G236D	1.000

dbSNP variants (sampled 300 via entrez): RS1000069066 (7:139246232 G>A), RS1000084221 (7:139326644 A>C,G), RS1000099104 (7:139298427 A>C), RS1000115882 (7:139315906 A>C,G), RS1000132512 (7:139281354 A>C,G), RS1000146610 (7:139246563 G>T), RS1000169416 (7:139320128 CAG>C), RS1000248070 (7:139275243 A>G), RS1000269890 (7:139314703 C>A,G,T), RS1000279474 (7:139240425 C>T), RS1000352385 (7:139306372 A>G,T), RS1000359399 (7:139265393 A>G), RS1000359434 (7:139287350 T>C,G), RS1000374871 (7:139281086 C>G,T), RS1000408570 (7:139298212 A>G)

Disease associations

OMIM: gene MIM:613841 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): autism spectrum disorder (MONDO:0005258)

Orphanet (1): NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, decreases methylation	7
sodium arsenite	decreases expression, increases abundance, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
FR900359	increases phosphorylation	1
TAK-243	increases sumoylation	1
geldanamycin	increases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	increases expression, affects binding, increases activity	1
arsenite	affects binding, decreases reaction	1
butyraldehyde	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
NSC 689534	affects binding, increases expression	1
Sunitinib	increases expression	1
Vorinostat	decreases expression	1
Arsenic	decreases expression, increases abundance	1
Copper	affects binding, increases expression	1
Diethylstilbestrol	increases expression	1
Methyl Methanesulfonate	increases expression	1
Tetrachlorodibenzodioxin	affects expression	1
Dronabinol	increases expression	1
Thimerosal	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Urethane	increases expression	1
p-Chloromercuribenzoic Acid	decreases expression	1
Magnetite Nanoparticles	increases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder